Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$43.48 USD
+1.01 (2.38%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $43.49 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
KYMR 43.48 +1.01(2.38%)
Will KYMR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KYMR
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
Other News for KYMR
Assured Guaranty, Kymera rise; BP, Helen of Troy fall, Tuesday, 7/9/2024
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
Kymera Therapeutics Shareholders Approve Key Governance Proposals
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics